Business Context and Reporting Period
Cvrx, Inc. (CVRX), an emerging growth company incorporated in Delaware, filed this Form 8-K on January 9, 2023. The filing serves to announce preliminary financial results for the quarter and fiscal year ended December 31, 2022, in preparation for the company's participation in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these preliminary results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference but not detailed within the body of this 8-K text.
Material Changes
No material changes or comparative financial data versus prior periods are disclosed in the text of this filing. The document solely references the existence of preliminary results for the period ended December 31, 2022.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific guidance, management commentary, risks, or contingencies are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 9, 2023) for the actual preliminary financial figures for Q4 and FY 2022.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the details of the presentation at the J.P. Morgan Healthcare Conference on January 11, 2023.
- Note that the financial data in this filing is preliminary and not audited.